TrialThe Lancet. Oncology2013

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

Brian I Rini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.